United Therapeutics Corporation (NASDAQ:UTHR) Files An 8-K Results of Operations and Financial ConditionItem 2.02. Results of Operations and Financial Condition.
On July27, 2017, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June30, 2017.
A copy of the press release is attached hereto as Exhibit99.1.
Item 9.01. Exhibits
This information shall not be deemed to be “filed” for the purposes of Section18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits
|
ExhibitNo.
|
DescriptionofExhibit
|
|
99.1
|
Press Release dated July27, 2017
|
UNITED THERAPEUTICS Corp ExhibitEX-99.1 2 a17-13352_3ex99d1.htm EX-99.1 Exhibit 99.1 For Immediate Release Contact: James Edgemond (301) 608-9292 Jedgemond@unither.com UNITED THERAPEUTICS CORPORATION REPORTS SECOND QUARTER 2017 FINANCIAL RESULTS Silver Spring,…To view the full exhibit click here
About United Therapeutics Corporation (NASDAQ:UTHR)
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. Its therapeutic products and product candidates include Prostacyclin Analogues, Phosphodiesterase Type 5 (PDE-5) Inhibitor and Monoclonal Antibody (MAb). Its Prostacyclin Analogues lead product is Remodulin (treprostinil) Injection. It also includes Tyvaso (treprostinil) Inhalation Solution and Orenitram (treprostinil) Extended-Release Tablets. Its subsidiary is developing another oral prostacyclin analogue for the treatment of pulmonary arterial hypertension (PAH) called esuberaprost. Its PDE-5 inhibitor is Adcirca (tadalafil) tablets are indicated for the treatment of PAH. Its Unituxin (dinutuximab) Injection in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid is indicated for the treatment of pediatric patients with neuroblastoma.